Abemaciclib in Patients with Oligodendroglioma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

May 15, 2025

Study Completion Date

May 15, 2027

Conditions
Oligodendroglioma, Adult
Interventions
DRUG

Abemaciclib 200 MG

Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Abramson Cancer Center at Penn Medicine

OTHER

collaborator

University of Pennsylvania

OTHER

lead

Stephen Bagley, MD, MSCE

OTHER

NCT03969706 - Abemaciclib in Patients with Oligodendroglioma | Biotech Hunter | Biotech Hunter